Veru (VERU) EV/EBITDA: History & Chart

Veru Inc.(VERU)

Biotechnology · Miami, FL

$2.47-0.08 (-3.14%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Veru Inc.

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.

Miami, FL

20 employees

www.verupharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mitchell S. Steiner

View full financials

VERU EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

EV/EBITDA RATIO AVG TTM

661.38x

EV/EBITDA RATIO AVG 3Y

661.38x

EV/EBITDA RATIO AVG 5Y

659.11x

EV/EBITDA RATIO AVG 10Y

158.31x

EV/EBITDA RATIO AVG 15Y

218.99x

EV/EBITDA RATIO AVG 20Y

421.88x

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Veru Inc. (VERU)	$39.64M	N/A	661.38x	661.38x	659.11x
Metagenomi, Inc. Common Stock (MGX)vs ›	$38.78M	N/A	N/A	N/A	N/A
Harvard Bioscience, Inc. (HBIO)vs ›	$38.61M	10.54x	9.64x	45.33x	52.62x
Incannex Healthcare Limited (IXHL)vs ›	$37.93M	N/A	N/A	N/A	N/A
Precipio, Inc. (PRPO)vs ›	$41.83M	N/A	1378.16x	1378.16x	1378.16x
BioStem Technologies, Inc. (BSEM)vs ›	$41.95M	N/A	7.89x	10.87x	10.87x
Filana Therapeutics, Inc. (FLNA)vs ›	$42.26M	N/A	N/A	N/A	N/A
Nano-X Imaging Ltd. (NNOX)vs ›	$42.83M	N/A	N/A	N/A	N/A
CVRx, Inc. (CVRX)vs ›	$42.99M	N/A	N/A	N/A	N/A
EUDA Health Holdings Limited (EUDA)vs ›	$36.21M	N/A	10986.66x	10986.66x	10986.66x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Veru Inc. (VERU)

$39.64M

N/A

661.38x

659.11x

Metagenomi, Inc. Common Stock (MGX)vs ›

$38.78M

N/A

Harvard Bioscience, Inc. (HBIO)vs ›

$38.61M

10.54x

9.64x

45.33x

52.62x

Incannex Healthcare Limited (IXHL)vs ›

$37.93M

N/A

Precipio, Inc. (PRPO)vs ›

$41.83M

N/A

1378.16x

BioStem Technologies, Inc. (BSEM)vs ›

$41.95M

N/A

7.89x

10.87x

Filana Therapeutics, Inc. (FLNA)vs ›

$42.26M

N/A

Nano-X Imaging Ltd. (NNOX)vs ›

$42.83M

N/A

CVRx, Inc. (CVRX)vs ›

$42.99M

N/A

EUDA Health Holdings Limited (EUDA)vs ›

$36.21M

N/A

10986.66x

EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Veru Inc. (VERU)?

The EV/EBITDA ratio for VERU stock is N/A.

What is the estimated TTM average EV/EBITDA ratio for Veru Inc. (VERU)?

The estimated TTM average EV/EBITDA ratio for VERU stock is 661.38x.

What is the estimated 3Y average EV/EBITDA ratio for Veru Inc. (VERU)?

The estimated 3Y average EV/EBITDA ratio for VERU stock is 661.38x.

What is the estimated 5Y average EV/EBITDA ratio for Veru Inc. (VERU)?

The estimated 5Y average EV/EBITDA ratio for VERU stock is 659.11x.

What is the estimated 10Y average EV/EBITDA ratio for Veru Inc. (VERU)?

The estimated 10Y average EV/EBITDA ratio for VERU stock is 158.31x.

What is the estimated 15Y average EV/EBITDA ratio for Veru Inc. (VERU)?

The estimated 15Y average EV/EBITDA ratio for VERU stock is 218.99x.

What is the estimated 20Y average EV/EBITDA ratio for Veru Inc. (VERU)?

The estimated 20Y average EV/EBITDA ratio for VERU stock is 421.88x.

DATE	EV/EBITDA RATIO
2022-02-09	27.70x
2022-02-08	25.62x
2022-02-07	24.72x
2022-02-04	23.70x
2022-02-03	22.81x
2022-02-02	23.53x
2022-02-01	24.90x
2022-01-31	22.93x
2022-01-28	20.18x
2022-01-27	19.05x
2022-01-26	19.88x
2022-01-25	20.60x
2022-01-24	21.38x
2022-01-21	21.14x
2022-01-20	22.99x
2022-01-19	23.59x
2022-01-18	24.84x
2022-01-14	27.05x
2022-01-13	27.05x
2022-01-12	28.24x
2022-01-11	30.15x
2022-01-10	23.76x
2022-01-07	24.48x
2022-01-06	25.08x
2022-01-05	25.44x
2022-01-04	28.48x
2022-01-03	28.96x
2021-12-31	27.05x
2021-12-30	27.76x
2021-12-29	27.17x
2021-12-28	27.76x
2021-12-27	29.73x
2021-12-23	29.44x
2021-12-22	29.32x
2021-12-21	29.73x
2021-12-20	28.66x
2021-12-17	29.73x
2021-12-16	28.48x
2021-12-15	29.02x
2021-12-14	27.35x
2021-12-13	28.36x
2021-12-10	29.20x
2021-12-09	30.27x
2021-12-08	32.18x
2021-12-07	29.79x
2021-12-06	28.78x
2021-12-03	28.06x
2021-12-02	112.16x
2021-12-01	111.36x
2021-11-30	123.25x
2021-11-29	123.04x
2021-11-26	128.69x
2021-11-24	131.10x
2021-11-23	129.69x
2021-11-22	125.06x
2021-11-19	129.89x
2021-11-18	136.14x
2021-11-17	146.82x
2021-11-16	154.27x
2021-11-15	159.11x
2021-11-12	168.17x
2021-11-11	152.06x
2021-11-10	140.77x
2021-11-09	144.80x
2021-11-08	146.82x
2021-11-05	142.59x
2021-11-04	147.02x
2021-11-03	140.37x
2021-11-02	141.18x
2021-11-01	142.18x
2021-10-29	136.74x
2021-10-28	138.15x
2021-10-27	135.13x
2021-10-26	137.35x
2021-10-25	138.15x
2021-10-22	135.13x
2021-10-21	140.17x
2021-10-20	141.78x
2021-10-19	142.39x
2021-10-18	138.56x
2021-10-15	145.21x
2021-10-14	148.23x
2021-10-13	149.44x
2021-10-12	143.19x
2021-10-11	141.78x
2021-10-08	142.39x
2021-10-07	144.20x
2021-10-06	138.96x
2021-10-05	143.80x
2021-10-04	140.77x
2021-10-01	142.59x
2021-09-30	144.00x
2021-09-29	143.80x
2021-09-28	150.65x
2021-09-27	160.72x
2021-09-24	154.88x
2021-09-23	158.50x
2021-09-22	148.63x
2021-09-21	147.62x
2021-09-20	142.59x
2021-09-17	152.26x
2021-09-16	149.03x
2021-09-15	149.84x
2021-09-14	150.24x
2021-09-13	155.28x
2021-09-10	156.29x
2021-09-09	163.54x
2021-09-08	159.11x
2021-09-07	162.13x
2021-09-03	171.40x
2021-09-02	171.00x
2021-09-01	151.25x
2021-08-31	151.86x
2021-08-30	147.42x
2021-08-27	155.28x
2021-08-26	132.92x
2021-08-25	135.13x
2021-08-24	134.33x
2021-08-23	129.09x
2021-08-20	120.22x
2021-08-19	112.16x
2021-08-18	108.94x
2021-08-17	109.55x
2021-08-16	116.60x
2021-08-13	124.66x
2021-08-12	1010.35x
2021-08-11	943.71x
2021-08-10	963.14x
2021-08-09	958.98x
2021-08-06	949.26x
2021-08-05	965.92x
2021-08-04	936.76x
2021-08-03	974.25x
2021-08-02	957.59x
2021-07-30	931.21x
2021-07-29	945.09x
2021-07-28	947.87x
2021-07-27	918.72x
2021-07-26	939.54x
2021-07-23	935.38x
2021-07-22	964.53x
2021-07-21	1006.18x
2021-07-20	981.19x
2021-07-19	938.15x
2021-07-16	940.93x
2021-07-15	943.71x
2021-07-14	952.04x
2021-07-13	979.80x
2021-07-12	1054.77x
2021-07-09	1049.22x
2021-07-08	1040.89x
2021-07-07	1033.95x
2021-07-06	1074.21x
2021-07-02	1070.04x
2021-07-01	1110.30x
2021-06-30	1097.81x
2021-06-29	1131.13x
2021-06-28	1185.27x
2021-06-25	1114.47x
2021-06-24	1118.63x
2021-06-23	1158.89x
2021-06-22	1158.89x
2021-06-21	1154.73x
2021-06-18	1146.40x
2021-06-17	1181.11x
2021-06-16	1153.34x
2021-06-15	1172.78x
2021-06-14	1203.32x
2021-06-11	1211.65x
2021-06-10	1213.04x
2021-06-09	1229.70x
2021-06-08	1232.47x
2021-06-07	1222.76x
2021-06-04	1189.44x
2021-06-03	1204.71x
2021-06-02	1246.36x
2021-06-01	1210.26x
2021-05-28	1203.32x
2021-05-27	1201.93x
2021-05-26	1178.33x
2021-05-25	1114.47x
2021-05-24	1117.24x
2021-05-21	1104.75x
2021-05-20	1114.47x
2021-05-19	1092.26x
2021-05-18	1090.87x
2021-05-17	1056.16x
2021-05-14	1027.00x
2021-05-13	983.97x
2021-05-12	821.24x
2021-05-11	849.68x
2021-05-10	838.30x
2021-05-07	886.08x
2021-05-06	834.89x
2021-05-05	997.57x
2021-05-04	987.33x
2021-05-03	1015.78x
2021-04-30	1003.26x
2021-04-29	1044.22x
2021-04-28	1035.12x
2021-04-27	1051.04x
2021-04-26	1070.38x
2021-04-23	1022.60x
2021-04-22	1022.60x
2021-04-21	1048.77x
2021-04-20	1007.81x
2021-04-19	1031.70x
2021-04-16	1069.25x
2021-04-15	1049.91x
2021-04-14	1121.58x
2021-04-13	1115.89x
2021-04-12	1107.93x
2021-04-09	1175.05x
2021-04-08	1178.46x
2021-04-07	1165.95x
2021-04-06	1229.65x
2021-04-05	1227.38x
2021-04-01	1271.75x
2021-03-31	1223.97x
2021-03-30	1244.44x
2021-03-29	1237.62x
2021-03-26	1287.68x
2021-03-25	1332.04x
2021-03-24	1378.69x
2021-03-23	1482.21x
2021-03-22	1565.26x
2021-03-19	1603.94x
2021-03-18	1562.99x
2021-03-17	1693.82x
2021-03-16	1684.72x
2021-03-15	1770.04x
2021-03-12	1700.64x
2021-03-11	1667.65x
2021-03-10	1549.34x
2021-03-09	1565.26x
2021-03-08	1411.68x
2021-03-05	1400.30x
2021-03-04	1384.38x
2021-03-03	1493.59x
2021-03-02	1591.43x
2021-03-01	1636.93x
2021-02-26	1569.81x
2021-02-25	1622.15x
2021-02-24	1721.12x
2021-02-23	1729.08x
2021-02-22	1867.88x
2021-02-19	1964.58x
2021-02-18	1797.34x
2021-02-17	1955.48x
2021-02-16	2252.40x
2021-02-12	2361.62x
2021-02-11	2139.78x
2017-02-09	86.02x
2017-02-08	87.70x
2017-02-07	87.70x
2017-02-06	88.55x
2017-02-03	87.70x
2017-02-02	89.39x
2017-02-01	89.39x
2017-01-31	85.18x

DATE

EV/EBITDA RATIO

2022-02-09

27.70x

2022-02-08

25.62x

2022-02-07

24.72x

2022-02-04

23.70x

2022-02-03

22.81x

2022-02-02

23.53x

2022-02-01

24.90x

2022-01-31

22.93x

2022-01-28

20.18x

2022-01-27

19.05x

2022-01-26

19.88x

2022-01-25

20.60x

2022-01-24

21.38x

2022-01-21

21.14x

2022-01-20

22.99x

2022-01-19

23.59x

2022-01-18

24.84x

2022-01-14

27.05x

2022-01-13

27.05x

2022-01-12

28.24x

2022-01-11

30.15x

2022-01-10

23.76x

2022-01-07

24.48x

2022-01-06

25.08x

2022-01-05

25.44x

2022-01-04

28.48x

2022-01-03

28.96x

2021-12-31

27.05x

2021-12-30

27.76x

2021-12-29

27.17x

2021-12-28

27.76x

2021-12-27

29.73x

2021-12-23

29.44x

2021-12-22

29.32x

2021-12-21

29.73x

2021-12-20

28.66x

2021-12-17

29.73x

2021-12-16

28.48x

2021-12-15

29.02x

2021-12-14

27.35x

2021-12-13

28.36x

2021-12-10

29.20x

2021-12-09

30.27x

2021-12-08

32.18x

2021-12-07

29.79x

2021-12-06

28.78x

2021-12-03

28.06x

2021-12-02

112.16x

2021-12-01

111.36x

2021-11-30

123.25x

2021-11-29

123.04x

2021-11-26

128.69x

2021-11-24

131.10x

2021-11-23

129.69x

2021-11-22

125.06x

2021-11-19

129.89x

2021-11-18

136.14x

2021-11-17

146.82x

2021-11-16

154.27x

2021-11-15

159.11x

2021-11-12

168.17x

2021-11-11

152.06x

2021-11-10

140.77x

2021-11-09

144.80x

2021-11-08

146.82x

2021-11-05

142.59x

2021-11-04

147.02x

2021-11-03

140.37x

2021-11-02

141.18x

2021-11-01

142.18x

2021-10-29

136.74x

2021-10-28

138.15x

2021-10-27

135.13x

2021-10-26

137.35x

2021-10-25

138.15x

2021-10-22

135.13x

2021-10-21

140.17x

2021-10-20

141.78x

2021-10-19

142.39x

2021-10-18

138.56x

2021-10-15

145.21x

2021-10-14

148.23x

2021-10-13

149.44x

2021-10-12

143.19x

2021-10-11

141.78x

2021-10-08

142.39x

2021-10-07

144.20x

2021-10-06

138.96x

2021-10-05

143.80x

2021-10-04

140.77x

2021-10-01

142.59x

2021-09-30

144.00x

2021-09-29

143.80x

2021-09-28

150.65x

2021-09-27

160.72x

2021-09-24

154.88x

2021-09-23

158.50x

2021-09-22

148.63x

2021-09-21

147.62x

2021-09-20

142.59x

2021-09-17

152.26x

2021-09-16

149.03x

2021-09-15

149.84x

2021-09-14

150.24x

2021-09-13

155.28x

2021-09-10

156.29x

2021-09-09

163.54x

2021-09-08

159.11x

2021-09-07

162.13x

2021-09-03

171.40x

2021-09-02

171.00x

2021-09-01

151.25x

2021-08-31

151.86x

2021-08-30

147.42x

2021-08-27

155.28x

2021-08-26

132.92x

2021-08-25

135.13x

2021-08-24

134.33x

2021-08-23

129.09x

2021-08-20

120.22x

2021-08-19

112.16x

2021-08-18

108.94x

2021-08-17

109.55x

2021-08-16

116.60x

2021-08-13

124.66x

2021-08-12

1010.35x

2021-08-11

943.71x

2021-08-10

963.14x

2021-08-09

958.98x

2021-08-06

949.26x

2021-08-05

965.92x

2021-08-04

936.76x

2021-08-03

974.25x

2021-08-02

957.59x

2021-07-30

931.21x

2021-07-29

945.09x

2021-07-28

947.87x

2021-07-27

918.72x

2021-07-26

939.54x

2021-07-23

935.38x

2021-07-22

964.53x

2021-07-21

1006.18x

2021-07-20

981.19x

2021-07-19

938.15x

2021-07-16

940.93x

2021-07-15

943.71x

2021-07-14

952.04x

2021-07-13

979.80x

2021-07-12

1054.77x

2021-07-09

1049.22x

2021-07-08

1040.89x

2021-07-07

1033.95x

2021-07-06

1074.21x

2021-07-02

1070.04x

2021-07-01

1110.30x

2021-06-30

1097.81x

2021-06-29

1131.13x

2021-06-28

1185.27x

2021-06-25

1114.47x

2021-06-24

1118.63x

2021-06-23

1158.89x

2021-06-22

1158.89x

2021-06-21

1154.73x

2021-06-18

1146.40x

2021-06-17

1181.11x

2021-06-16

1153.34x

2021-06-15

1172.78x

2021-06-14

1203.32x

2021-06-11

1211.65x

2021-06-10

1213.04x

2021-06-09

1229.70x

2021-06-08

1232.47x

2021-06-07

1222.76x

2021-06-04

1189.44x

2021-06-03

1204.71x

2021-06-02

1246.36x

2021-06-01

1210.26x

2021-05-28

1203.32x

2021-05-27

1201.93x

2021-05-26

1178.33x

2021-05-25

1114.47x

2021-05-24

1117.24x

2021-05-21

1104.75x

2021-05-20

1114.47x

2021-05-19

1092.26x

2021-05-18

1090.87x

2021-05-17

1056.16x

2021-05-14

1027.00x

2021-05-13

983.97x

2021-05-12

821.24x

2021-05-11

849.68x

2021-05-10

838.30x

2021-05-07

886.08x

2021-05-06

834.89x

2021-05-05

997.57x

2021-05-04

987.33x

2021-05-03

1015.78x

2021-04-30

1003.26x

2021-04-29

1044.22x

2021-04-28

1035.12x

2021-04-27

1051.04x

2021-04-26

1070.38x

2021-04-23

1022.60x

2021-04-22

1022.60x

2021-04-21

1048.77x

2021-04-20

1007.81x

2021-04-19

1031.70x

2021-04-16

1069.25x

2021-04-15

1049.91x

2021-04-14

1121.58x

2021-04-13

1115.89x

2021-04-12

1107.93x

2021-04-09

1175.05x

2021-04-08

1178.46x

2021-04-07

1165.95x

2021-04-06

1229.65x

2021-04-05

1227.38x

2021-04-01

1271.75x

2021-03-31

1223.97x

2021-03-30

1244.44x

2021-03-29

1237.62x

2021-03-26

1287.68x

2021-03-25

1332.04x

2021-03-24

1378.69x

2021-03-23

1482.21x

2021-03-22

1565.26x

2021-03-19

1603.94x

2021-03-18

1562.99x

2021-03-17

1693.82x

2021-03-16

1684.72x

2021-03-15

1770.04x

2021-03-12

1700.64x

2021-03-11

1667.65x

2021-03-10

1549.34x

2021-03-09

1565.26x

2021-03-08

1411.68x

2021-03-05

1400.30x

2021-03-04

1384.38x

2021-03-03

1493.59x

2021-03-02

1591.43x

2021-03-01

1636.93x

2021-02-26

1569.81x

2021-02-25

1622.15x

2021-02-24

1721.12x

2021-02-23

1729.08x

2021-02-22

1867.88x

2021-02-19

1964.58x

2021-02-18

1797.34x

2021-02-17

1955.48x

2021-02-16

2252.40x

2021-02-12

2361.62x

2021-02-11

2139.78x

2017-02-09

86.02x

2017-02-08

87.70x

2017-02-07

87.70x

2017-02-06

88.55x

2017-02-03

87.70x

2017-02-02

89.39x

2017-02-01

89.39x

2017-01-31

85.18x

EV/EBITDA Ratio: N/A

VERU EV/EBITDA Ratio Chart

VERU Average EV/EBITDA Ratio Chart

VERU EV/EBITDA Ratio Metrics

VERU Competitors' EV/EBITDA Ratio

EV/EBITDA Ratio Formula & Definition

EV/EBITDA Ratio FAQ

VERU EV/EBITDA Ratio History

Related Metrics